SUBSCRIBE
SUBSCRIBE
News   Policy

Amgen’s (JOBS) Bone Drug May Face Delays In FDA Decision

October 16, 2009 | 
1 min read
Bookmark and Share

NEW YORK (Dow Jones)--Biotech investors had circled Oct. 19 as the day that Amgen Inc.'s (AMGN) osteoporosis drug denosumab gets approved, but they may have to wait longer.
Regulatory
Amgen Food and Drug Administration (FDA)
MORE ON THIS TOPIC
FDA
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
May 20, 2026
 · 
1 min read
 · 
Jef Akst
The COVID-19 vaccine in glass bottles for prevention, immunization, and treatment of coronavirus infection on a green background. Space for text. Concept of medical and vaccine.
COVID-19
FDA’s own report shows no child deaths definitively caused by COVID vaccination
May 19, 2026
 · 
3 min read
 · 
Tristan Manalac
Minimal Clip Art Collage. Pop Vector Design Composition with bright bold geometric shapes, halftone objects for ad, animation etc
Approvals
AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs
May 18, 2026
 · 
1 min read
 · 
Tristan Manalac
Business people and concepts vector art exit
Government
Prasad ally Szarama exits CBER after 3 weeks as FDA cleanout continues
May 18, 2026
 · 
2 min read
 · 
Tristan Manalac